Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
TBC avapritinib Advanced Systemic Mastocytosis Pending
TBC ferric carboxymaltose Iron deficiency anemia Pending
NA icatibant Hereditary Angioedema Active
TBC rozanolixizumab Generalized myasthenia gravis (gMG). Pending
TBC talquetamab Relapsed or refractory multiple myeloma Pending
Treanda (in combination with rituximab) Bendamustine hydrochloride Chronic Lymphocytic Leukemia Withdrawn
Imbruvica Ibrutinib
TBC etonogestrel Prevention of pregnancy Withdrawn
Tecentriq Atezolizumab Withdrawn
TBC filgotinib Arthritis, Rheumatoid Withdrawn